158 related articles for article (PubMed ID: 20074164)
1. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation.
Tsai MC; Wang JH; Hung CH; Kee KM; Yen YH; Lee CM; Hu TH; Chen CH; Lu SN
J Gastroenterol Hepatol; 2010 Mar; 25(3):605-12. PubMed ID: 20074164
[TBL] [Abstract][Full Text] [Related]
2. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation.
Fontana RJ; Hamidullah H; Nghiem H; Greenson JK; Hussain H; Marrero J; Rudich S; McClure LA; Arenas J
Liver Transpl; 2002 Dec; 8(12):1165-74. PubMed ID: 12474157
[TBL] [Abstract][Full Text] [Related]
3. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy.
Kao WY; Chiou YY; Hung HH; Su CW; Chou YH; Wu JC; Huo TI; Huang YH; Wu WC; Lin HC; Lee SD
Clin Radiol; 2012 May; 67(5):429-36. PubMed ID: 22153231
[TBL] [Abstract][Full Text] [Related]
4. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma.
Harrison LE; Koneru B; Baramipour P; Fisher A; Barone A; Wilson D; Dela Torre A; Cho KC; Contractor D; Korogodsky M
J Am Coll Surg; 2003 Nov; 197(5):759-64. PubMed ID: 14585410
[TBL] [Abstract][Full Text] [Related]
5. Tumor markers after radiofrequency ablation therapy for hepatocellular carcinoma.
Ogawa C; Kudo M; Minami Y; Chung H; Kawasaki T
Hepatogastroenterology; 2008; 55(85):1454-7. PubMed ID: 18795710
[TBL] [Abstract][Full Text] [Related]
6. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.
Poon RT; Lau C; Pang R; Ng KK; Yuen J; Fan ST
Ann Surg Oncol; 2007 Jun; 14(6):1835-45. PubMed ID: 17406950
[TBL] [Abstract][Full Text] [Related]
7. Incomplete ablation after radiofrequency ablation of hepatocellular carcinoma: analysis of risk factors and prognostic factors.
Lam VW; Ng KK; Chok KS; Cheung TT; Yuen J; Tung H; Tso WK; Fan ST; Poon RT
Ann Surg Oncol; 2008 Mar; 15(3):782-90. PubMed ID: 18095030
[TBL] [Abstract][Full Text] [Related]
8. [The factors related to the prognosis of solitary hepatocellular carcinoma after radiofrequency ablation].
Chung IK; Park MJ; Kwon KT; Park YD; Chung YJ; Jeon SW; Lee MK; Seo HE; Lee YD; Cho CM; Tak WY; Kweon YO; Kim SK; Choi YH
Korean J Hepatol; 2005 Dec; 11(4):371-80. PubMed ID: 16380666
[TBL] [Abstract][Full Text] [Related]
9. Are both PIVKA-II and alpha-fetoprotein necessary in follow-up management after hepatic resection for hepatocellular carcinoma?
Koh T; Taniguchi H; Katoh H; Kunishima S; Yamaguchi A; Yamagishi H
Hepatogastroenterology; 2002; 49(48):1615-8. PubMed ID: 12397748
[TBL] [Abstract][Full Text] [Related]
10. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response.
Guglielmi A; Ruzzenente A; Pachera S; Valdegamberi A; Sandri M; D'Onofrio M; Iacono C
Am J Gastroenterol; 2008 Mar; 103(3):597-604. PubMed ID: 17970836
[TBL] [Abstract][Full Text] [Related]
11. alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.
Chen LT; Liu TW; Chao Y; Shiah HS; Chang JY; Juang SH; Chen SC; Chuang TR; Chin YH; Whang-Peng J
Aliment Pharmacol Ther; 2005 Aug; 22(3):217-26. PubMed ID: 16091059
[TBL] [Abstract][Full Text] [Related]
12. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors.
Yin XY; Xie XY; Lu MD; Xu HX; Xu ZF; Kuang M; Liu GJ; Liang JY; Lau WY
Cancer; 2009 May; 115(9):1914-23. PubMed ID: 19241423
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients.
Xu HX; Lu MD; Xie XY; Yin XY; Kuang M; Chen JW; Xu ZF; Liu GJ
Clin Radiol; 2005 Sep; 60(9):1018-25. PubMed ID: 16124984
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
Montella L; Addeo R; Caraglia M; Faiola V; Guarrasi R; Vincenzi B; Palmeri A; Capasso E; Nocera V; Tarantino L; Ariete M; Martorelli A; Del Prete S
Oncol Rep; 2008 Aug; 20(2):385-90. PubMed ID: 18636202
[TBL] [Abstract][Full Text] [Related]
15. Significance of alpha-fetoprotein mRNA level in hepatocellular carcinoma patients treated with radiofrequency ablation.
Du XL; Ma QJ; Wu T; Bao GQ; Lu JG; Chu YK
Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):172-5. PubMed ID: 17374577
[TBL] [Abstract][Full Text] [Related]
16. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma.
Kobayashi M; Ikeda K; Kawamura Y; Yatsuji H; Hosaka T; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Kumada H
Cancer; 2009 Feb; 115(3):571-80. PubMed ID: 19117347
[TBL] [Abstract][Full Text] [Related]
17. [Comparision of different interventional therapies for primary liver cancer].
Liu YM; Qin H; Wang CB; Fang XH; Ma QY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):232-5. PubMed ID: 17649645
[TBL] [Abstract][Full Text] [Related]
18. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.
Ueno S; Sakoda M; Kubo F; Hiwatashi K; Tateno T; Baba Y; Hasegawa S; Tsubouchi H;
J Hepatobiliary Pancreat Surg; 2009; 16(3):359-66. PubMed ID: 19300896
[TBL] [Abstract][Full Text] [Related]
19. [Prognosis and risk factors for recurrence of small liver cancer after a single session of percutaneous radiofrequency ablation].
Xia JL; Ye SL; Zou JH; Ren ZG; Gan YH; Wang YH; Chen Y; Ge NL; Tang ZY; Yang BH
Ai Zheng; 2004 Sep; 23(9):977-80. PubMed ID: 15363186
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
Toyoda H; Kumada T; Kaneoka Y; Osaki Y; Kimura T; Arimoto A; Oka H; Yamazaki O; Manabe T; Urano F; Chung H; Kudo M; Matsunaga T
J Hepatol; 2008 Aug; 49(2):223-32. PubMed ID: 18571271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
